In a move to bolster its Sample technologies division, QIAGEN N.V. has entered into a definitive agreement to fully acquire Parse Biosciences for an upfront payment of approximately US$225 million in cash, with additional milestone payments of up to US$55 million, expected to close in December 2025. The acquisition gives QIAGEN access to Parse’s Evercode platform which supports instrument-free processing of millions to billions of cells and complements QIAGEN’s existing Sample to Insight offerings and its bioinformatics arm, QIAGEN Digital Insights (QDI). QIAGEN CEO Thierry Bernard stated, “The addition of the Parse team to QIAGEN will significantly strengthen our offerings in one of the most dynamic areas of life science … By combining Parse with our Sample technologies portfolio and QDI bioinformatics offering, we can provide researchers with the tools to generate the massive datasets required to build predictive virtual cell models that fuel AI-based drug discovery.” Meanwhile, Parse co-founder and CEO Alex Rosenberg added, “Parse was founded to make single-cell sequencing accessible to any lab … As our team joins QIAGEN, we want to accelerate that mission and extend the reach of our technology to more customers around the world.” The deal positions QIAGEN to capitalise on the highly-growth single-cell market (expected to grow from about US$1.2 billion in 2024 to US$2.1 billion by 2029), driven by demand for large-scale cellular data and AI-powered drug discovery efforts. Under the agreement, Parse is projected to contribute approximately US$40 million in sales in full‐year 2026 and become accretive to adjusted EPS beginning in 2028.
Also Read: Innate Pharma gets FDA nod for Phase 3 TELLOMAK trial
The integration of Parse’s instrumentation-free chemistry, large-scale barcoding platform (which already supports over 3,000 labs in more than 40 countries) and high-throughput service capabilities (including 2.5 billion cells per year via its GigaLab service) complements QIAGEN’s broad global reach in molecular technologies and data analytics. With strong synergy across high-throughput sample-to-insight workflows and the growing demand for single-cell datasets in pharma and biotech, QIAGEN’s acquisition of Parse marks a strategic step deeper into AI-enabled biology and predictive modelling.